Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo

被引：0
|
作者：
Kim, C. [1 ]
Bryant, J. [1 ]
Horne, Z. [1 ]
Geyer, C. E. [1 ]
Wickerham, D. L. [1 ]
Wolmark, N. [1 ]
Paik, S. [1 ]
机构：
[1] NSABP Operat & Biostat Ctr, Pittsburgh, PA USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：340 / 341
页数：2
相关论文
共 50 条
  • [1] Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo.
    Kim, C
    Bryant, J
    Horne, Z
    Geyer, CE
    Wickerham, DL
    Wolmark, N
    Paik, S
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S6 - S7
  • [2] Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer
    Varga, Zsuzsanna
    Tubbs, Raymond R.
    Wang, Zhen
    Sun, Yang
    Noske, Aurelia
    Kradolfer, Doris
    Bosshard, Giovanna
    Jochum, Wolfram
    Moch, Holger
    Oehlschlegel, Christian
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (03) : 925 - 935
  • [3] Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer
    Zsuzsanna Varga
    Raymond R. Tubbs
    Zhen Wang
    Yang Sun
    Aurelia Noske
    Doris Kradolfer
    Giovanna Bosshard
    Wolfram Jochum
    Holger Moch
    Christian Öhlschlegel
    Breast Cancer Research and Treatment, 2012, 132 : 925 - 935
  • [4] HER2/neu and cMYC alterations in breast lesions from women with and without a family history of breast cancer.
    Jenkins, RB
    Reynolds, CA
    Soderberg, CA
    Melder, DC
    Couch, FJ
    Hartmann, LC
    AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (04) : A131 - A131
  • [5] Overall cost benefit of adjuvant Trastuzumab (Adj Trastuz) therapy for early breast cancer: Impact of co-expression of Her2/Neu with cMYC, PTEN or TOPO II
    Ragaz, Joseph
    Spinelli, John J.
    ANNALS OF ONCOLOGY, 2006, 17 : 95 - 95
  • [6] FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis
    Chen, Shinan
    Qiu, Yan
    Guo, Peng
    Pu, Tianjie
    Feng, Ye
    Bu, Hong
    ONCOLOGY LETTERS, 2018, 15 (06) : 8206 - 8214
  • [7] High resolution representational oligonucleotide microarray analysis (ROMA) suggests that TOPO2 and HER2 co-amplification is uncommon in human breast cancer.
    McArthur, H. L.
    Tan, L. K.
    Patil, S.
    Wigler, M.
    Hudis, C. A.
    Hicks, J.
    Norton, L.
    CANCER RESEARCH, 2009, 69 (02) : 163S - 163S
  • [8] HER2 Phosphorylates and Destabilizes Pro-Apoptotic PUMA, Leading to Antagonized Apoptosis in Cancer Cells
    Carpenter, Richard L.
    Han, Woody
    Paw, Ivy
    Lo, Hui-Wen
    PLOS ONE, 2013, 8 (11):
  • [9] Breast cancers with EGFR and HER2 co-amplification favor distant metastasis and poor clinical outcome
    Guo, Peng
    Pu, Tianjie
    Chen, Shinan
    Qiu, Yan
    Zhong, Xiaorong
    Zheng, Hong
    Chen, Lina
    Bu, Hong
    Ye, Feng
    ONCOLOGY LETTERS, 2017, 14 (06) : 6562 - 6570
  • [10] HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab
    Ithimakin, Suthinee
    Day, Kathleen C.
    Malik, Fayaz
    Zen, Qin
    Dawsey, Scott J.
    Bersano-Begey, Tom F.
    Quraishi, Ahmed A.
    Ignatoski, Kathleen Woods
    Daignault, Stephanie
    Davis, April
    Hall, Christopher L.
    Palanisamy, Nallasivam
    Heath, Amber N.
    Tawakkol, Nader
    Luther, Tahra K.
    Clouthier, Shawn G.
    Chadwick, Whitney A.
    Day, Mark L.
    Kleer, Celina G.
    Thomas, Dafydd G.
    Hayes, Daniel F.
    Korkaya, Hasan
    Wicha, Max S.
    CANCER RESEARCH, 2013, 73 (05) : 1635 - 1645
12345